OSAKA, Japan – (COMMERCIAL THREAD) – Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO: 4502) (NYSE: TAK) today announced that it has filed its corporate governance report with the Tokyo Stock Exchange (“TSE”) in accordance with the regulations * of the TSE listed companies. The report is available on Takeda’s website at: https://www.takeda.com/who-we-are/corporate-governance/.
This report is prepared on the basis of the principles of the Corporate Governance Code in effect on June 1, 2018. Takeda will submit a revised corporate governance report based on the Corporate Governance Code in effect on June 11, 2021, d ‘here the end. of December 2021.
Takeda’s latest corporate governance report can be viewed on the information disclosure site operated by the Japan Exchange Group, which includes the TSE and other exchanges in Japan at:
Takeda has also provided the English version of the corporate governance report to the United States Securities and Exchange Commission (the “SEC”), available at www.sec.gov.
For general information on Corporate Governance Report, please refer to the Japan Exchange Group website at: https://www.jpx.co.jp/english/equities/listing/ cg / 01.html.
In addition, Takeda’s corporate governance policy as well as general environmental, company and governance information is explained in detail in its 2021 integrated annual report for the year ended March 31, 2021. This report is available on Takeda’s website at: https: // air.takeda.com
* TSE Regulation respecting the registration of securities [Rule 419].
About Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited (TOKYO: 4502) (NYSE: TAK) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discovering and delivering life-transforming treatments, guided by our commitment to patients, our staff and the planet. Takeda focuses its R&D efforts in four therapeutic areas: oncology, rare genetics and hematology, neuroscience and gastroenterology (GI). We also make targeted investments in R&D in plasma-derived therapies and vaccines. We are focused on developing highly innovative medicines that help make a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a pipeline. robust and diverse. Our employees are committed to improving the quality of life for patients and working with our healthcare partners in approximately 80 countries and regions. For more information, visit https://www.takeda.com.